We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4183:TSEMitsui Chemicals, Inc. Analysis

Data as of 2026-06-12 - not real-time

NT$13.65

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The stock is trading at TWD 13.65, just below the short‑term resistance of TWD 13.80 and marginally above the 20‑day SMA of TWD 13.16, while remaining under both the 50‑day (TWD 14.17) and 200‑day (TWD 16.63) averages, signaling a bearish longer‑term bias. Technical indicators are mixed: RSI sits at a neutral 51.7, the MACD histogram is positive indicating a brief bullish signal, yet the MACD line remains negative and volume is on a decreasing trend, reinforcing downside pressure. Volatility is elevated at 30.8% over the past 30 days and the max drawdown of 41% underscores the stock’s price fragility. On the fundamentals side, revenue has collapsed by nearly 50% YoY, margins are thin to negative (gross 17.2%, operating –24.1%, profit –4.8%), and earnings per share are –0.33 with no forward earnings expected. Despite these challenges, the company offers a high dividend yield of 4.91%, though the payout is not supported by earnings or positive cash flow, raising sustainability concerns. Overall, the equity appears undervalued relative to its book (P/B 1.21) and sales (P/S 0.73) but is weighed down by deteriorating financial performance and heightened risk factors.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price hovering just below resistance with bearish longer‑term SMA alignment
  • Decreasing volume and high short‑term volatility
  • Negative earnings and operating cash flow

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Attractive dividend yield despite sustainability doubts
  • Undervalued book and sales multiples
  • Continued revenue contraction and margin weakness

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Persistent earnings losses and zero forward EPS
  • High max drawdown and elevated price volatility
  • Regulatory and growth headwinds in the medical‑device sector

Key Metrics & Analysis

Financial Health

Revenue Growth-49.30%
Profit Margin-4.81%
ROE-7.44%
Debt/Equity50.84
P/B Ratio1.2
Op. Cash FlowNT$-28120000
Industry P/E24.9

Technical Analysis

TrendBearish
RSI51.7
SupportNT$11.60
ResistanceNT$13.80
MA 20NT$13.16
MA 50NT$14.17
MA 200NT$16.63
MACDBullish
VolumeDecreasing
Fear & Greed Index86.71

Valuation

GradeUndervalued
TypeValue
Dividend Yield4.91%

Risk Assessment

Beta-0.09
Volatility30.84%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.